Core Viewpoint - Shanghai Pharmaceuticals is experiencing a situation of revenue growth without profit increase, prompting a structural optimization strategy [1][8]. Group 1: Company Actions - On February 4, Shanghai Pharmaceuticals announced plans to publicly transfer 30% of its stake in China-America Shanghai Bristol-Myers Squibb Co., with a minimum listing price of 1.023 billion yuan [1][8]. - The company is focusing on innovation, with a new drug pipeline consisting of 56 projects, including 44 innovative drugs [6][14]. Group 2: Shareholder Changes - In October 2025, Shanghai Pharmaceuticals' major shareholder, Shanghai Pharmaceuticals Holding Group, increased its stake from 23.303% to 38.487%, enhancing the stability of the shareholding structure [6][13]. - The second largest shareholder is Yunnan Baiyao, holding 17.95% [6][13]. Group 3: Financial Performance - For the first three quarters of 2025, Shanghai Pharmaceuticals reported revenue of 215.072 billion yuan, a year-on-year increase of 2.60%, while net profit attributable to shareholders was 5.147 billion yuan, up 26.96% [15]. - However, the company's net profit excluding non-recurring items decreased by 26.79%, and operating cash flow fell by 15.56% [15].

Core Viewpoint - Shanghai Pharmaceuticals has officially terminated its cooperation agreement with Guizhou Shengnuo Biotechnology regarding the new acid suppressant project X842, based on a comprehensive assessment of the external market and overall business development plans of all parties involved [1][2]. Group 1: Termination Agreement Details - The termination agreement stipulates that Guizhou Shengnuo must return a total of 110 million yuan (approximately 15.5 million USD) in advance payment and development registration milestone fees to Shanghai Pharmaceuticals within 45 working days after signing the agreement [2]. - Guizhou Shengnuo is also required to pay a fund occupation fee at an annualized interest rate of 3% for the amount returned, calculated based on the actual days of fund occupation [2]. - The dispute resolution mechanism will follow the original agreement, applying Chinese law and submitting disputes to the China International Economic and Trade Arbitration Commission in Beijing [2]. Group 2: Market Context and Implications - The termination of the cooperation is seen as a result of significant changes in the market environment for the X842 project over the four years of collaboration, indicating that the competitive landscape for acid suppressants has become more intense [2]. - The market for proton pump inhibitors (PPIs) already has several established products, and the development progress and market acceptance of the new acid suppressants may not have met expectations [2]. - Shanghai Pharmaceuticals emphasized that the termination will not have a significant impact on its financial status or operational results, and it does not impose any additional unfavorable obligations on its subsidiary, Shanghai Shenyin [3].

Group 1 - The core point of the announcement is the termination of the cooperation agreement between Shanghai Pharmaceuticals and Guizhou Shengnuo Biotech, which was based on mutual agreement and does not impose additional obligations on Shanghai Pharmaceuticals [3][4]. - The original cooperation agreement was signed on October 8, 2021, granting Shanghai Pharmaceuticals exclusive rights for the production and industrial sales of the new acid suppressant X842 in China [2]. - The termination agreement stipulates that Shanghai Pharmaceuticals will receive a refund of 110 million yuan within 45 working days after the agreement is signed, along with interest at an annual rate of 3% [3]. Group 2 - Shanghai Pharmaceuticals' subsidiary, Shenyang Dongying, has received approval from the National Medical Products Administration for the production of Minoxidil solution, which is classified as a Class 3 chemical drug [7][8]. - The Minoxidil solution is available in two specifications: 2% and 5%, with the 2% formulation used for treating male pattern baldness and alopecia, while the 5% formulation is restricted to male use [9]. - The market for Minoxidil topical formulations in China was valued at approximately 236 million yuan in 2024, indicating a significant market opportunity for the newly approved product [10].

Core Viewpoint - Shanghai Pharmaceuticals has terminated its cooperation agreement with Guizhou Shengnuo Biotech regarding the X842 project, leading to the return of a 110 million yuan upfront payment and associated fees [1][2]. Group 1: Agreement Details - On October 8, 2021, Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyu, signed a cooperation agreement with Guizhou Shengnuo for the production and sales of the new acid suppressant X842, granting exclusive rights in China, including Hong Kong, Macau, and Taiwan [1]. - The termination agreement was signed after a comprehensive market assessment and mutual discussions, with the original agreement remaining effective until the termination agreement takes effect [1]. Group 2: Financial Terms - The termination agreement stipulates that Guizhou Shengnuo must return the 110 million yuan upfront payment and development milestone fees to Shanghai Shiyu within 45 working days after the agreement takes effect, along with an annualized interest of 3% on the funds [2]. - On December 5, 2025, Shanghai Shiyu received the 110 million yuan payment, leading to the automatic termination of the original cooperation agreement, which no longer holds legal binding force [2].

Core Viewpoint - Shanghai Pharmaceuticals has terminated its cooperation agreement with Guizhou Shengnuo Biotechnology regarding the new acid suppressant project X842, and has received a refund of 110 million yuan for the initial payment and development milestone fees [1][2]. Group 1: Termination of Cooperation - The termination agreement was signed on November 18, 2025, and the original cooperation agreement will automatically terminate after the refund is received [1]. - The company stated that this termination will not have a significant impact on its financial status or operating results [2]. Group 2: New Product Approval - On the same day, the company announced that its subsidiary, Jiangsu Dongying Pharmaceutical, received a drug registration certificate for Minoxidil lotion from the National Medical Products Administration [2]. - Minoxidil lotion is used for treating male pattern baldness and alopecia, with a market size of 2.361 billion yuan in China for 2024 [3]. - The approval is expected to enhance the market share and competitiveness of the product, while also providing valuable experience for future generic drug applications [3].

Core Viewpoint - Shanghai Pharmaceuticals announced the termination of the cooperation agreement related to the X842 project with Shengnuo Biotech, which will not significantly impact the company's financial and operational performance [1] Group 1 - In 2021, Shanghai Pharmaceuticals' wholly-owned subsidiary, Shanghai Pharmaceuticals Xinyi, signed an original cooperation agreement with Guizhou Shengnuo and Jiangsu Shengnuo for the X842 project, granting exclusive production and sales rights [1] - On November 18, 2025, Shanghai Pharmaceuticals Xinyi and Shengnuo Biotech signed a termination agreement, which became effective upon the receipt of a refund of 110 million yuan [1] - The original cooperation agreement automatically terminated on December 5, 2025, after the receipt of the refund [1]